News Story: Full Text
Sponsored By
Cedars-Sinai Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Publication of Preclinical IL13-PE38 Data Shows Potential of Neopharm Agent Against Glioblastoma Tumors (Business Wire)NeoPharm, Inc. announced today publication of data on its product IL13-PE38, a chimeric protein composed of human interleukin-13 and a truncated form of Pseudomonas exotoxin. In an experimental, preclinical tumor study, recently published in International Journal of Cancer, IL13-PE38 evidenced significant regression of glioblastoma tumors when injected into such tumors.- Apr 11 7:01 AM ET



Website: http://biz.yahoo.com/bw/010411/0049.html

Posted on: 04/11/2001

"Yahoo - Publication of Preclinical IL13-PE38 Data Shows Potential of Neopharm Agent Against Glioblastoma Tumors"
Yahoo! Finance Finance Home - Yahoo! - Help
Business Wire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
NEOL
23.25
+0.67
delayed 20 mins - disclaimer
Wednesday April 11, 7:01 am Eastern Time

Press Release

Publication of Preclinical IL13-PE38 Data Shows Potential of Neopharm Agent Against Glioblastoma Tumors

LAKE FOREST, Ill.--(BUSINESS WIRE)--APRIL 11, 2001--NeoPharm, Inc. (Nasdaq National Market: NEOL) announced today publication of data on its product IL13-PE38, a chimeric protein composed of human interleukin-13 (IL-13) and a truncated form of Pseudomonas exotoxin (PE38QQR). In an experimental, preclinical tumor study, recently published in International Journal of Cancer (Int. J. Cancer: 2001; 92, 168-175), IL13-PE38 evidenced significant regression of glioblastoma tumors when injected into such tumors. Neopharm has exclusively licensed IL13-PE38 from the National Cancer Institute (NCI) and Food and Drug Administration (FDA) for worldwide development. Currently, IL13-PE38 is in Phase I/II clinical trials for the treatment of refractory glioblastoma multiform, a lethal form of brain cancer.

Imran Ahmad, Vice President Research and Development of NeoPharm said, "Although there is much further study needed, we believe that IL13-PE38 has great promise for glioblastoma therapy and helping patients with this devastating cancer."

NeoPharm, Inc., based in Lake Forest, IL, is a publicly traded biopharmaceutical company dedicated to the discovery and commercialization of new and innovative cancer drugs for therapeutic applications. The Company has a broad portfolio of cancer compounds in various stages of development.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's drug development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Companies' drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Companies' drug candidates that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets and other risks detailed from time to time in filings the Company makes with Securities and Exchange Commission including their annual reports of Form 10-K and their quarterly reports on Forms 10-Q. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.


Contact:
     NeoPharm, Inc.
     Larry Kenyon, 847/295-8678
               or
     Investors please contact:
     MontRidge, LLC
     Janet Dally, 203/894-8038

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:NeoPharm Inc (NasdaqNM:NEOL - news)
Related News Categories: biotech, computers, health care, internet, medical/pharmaceutical, publishing, telecom

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Questions or Comments?
"
Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740